ValuEngine downgraded shares of Insys Therapeutics (NASDAQ:INSY) from a buy rating to a hold rating in a report released on Thursday.
Separately, Zacks Investment Research raised Insys Therapeutics from a sell rating to a hold rating in a research report on Thursday, October 11th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus price target of $7.67.
Insys Therapeutics stock opened at $4.91 on Thursday. Insys Therapeutics has a one year low of $4.80 and a one year high of $14.00.
Institutional investors have recently added to or reduced their stakes in the stock. Jane Street Group LLC purchased a new position in Insys Therapeutics in the third quarter worth about $113,000. Tower Research Capital LLC TRC purchased a new position in Insys Therapeutics in the second quarter worth about $131,000. Creative Planning purchased a new position in Insys Therapeutics in the third quarter worth about $153,000. MetLife Investment Advisors LLC purchased a new position in Insys Therapeutics in the third quarter worth about $223,000. Finally, BNP Paribas Arbitrage SA boosted its position in Insys Therapeutics by 47.4% in the second quarter. BNP Paribas Arbitrage SA now owns 31,105 shares of the specialty pharmaceutical company’s stock worth $225,000 after purchasing an additional 10,001 shares during the last quarter. 17.22% of the stock is currently owned by institutional investors.
Insys Therapeutics Company Profile
Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
Read More: What is dollar cost averaging (DCA)?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.